RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma

  • Sisi Wang
  • Bo Wang
  • Chao Xie
  • Daoxiong YeEmail author


RET proto-oncogene (RET) mutations were proved to be related to the development of medullary thyroid carcinoma (MTC). We aimed to analyze the role of RET mutations in cervical lymph node metastasis in patients with MTC. Forty-nine patients with preoperatively diagnosed MTC by fine-needle aspiration cytology (FNAC) who underwent bilateral total thyroidectomy with cervical lymphadenectomy were included. Postoperative RET gene test and pathological analysis were performed with the surgical specimens; serum calcitonin (Ctn) and carcinoembryonic antigen (CEA) levels were tested pre- and postoperatively, to evaluate the association between RET mutations and cervical lymph node metastasis in MTC. In these 49 patients, the RET mutation rates of Exon 11, Exon 10, Exon 11&13, Exon 13, and Exon 16 were 20.4%, 4.1%, 38.8%, 22.4%, and 0%, respectively. The lymph node metastasis rates of patients with RET mutation in the central and lateral compartments were 71.4% and 64.3%, respectively, versus 28.6% and 14.3% of patients without RET mutation. The preoperative basal serum levels of Ctn (234.8 ± 188.4 vs. 44.4 ± 27.5, p < 0.01) and postoperative Ctn (49.8 ± 86.4 vs. 3.7 ± 2.2, p = 0.001) in MTC patients with RET mutations were significantly higher than those in MTC patients without RET mutation. In addition, the preoperative (50.2 ± 76.7 vs. 7.4 ± 6.8, p = 0.001) and postoperative serum levels of CEA (13.2 ± 19.5 vs. 1.3 ± 1.6, p < 0.01) in MTC patients with RET mutations were significantly higher than those in MTC patients without RET mutation (p < 0.05). RET mutation was related to cervical lymph node metastasis in patients with MTC, especially the mutation in Exon 11&13. Patients with RET mutation in Exon 11&13 might be regarded as the predictor for prophylactic ipsilateral total cervical lymphadenectomy even without clear evidence of lateral cervical lymph node metastasis.


Medullary thyroid carcinoma RET proto-oncogene mutation Cervical lymph node metastasis Prognostic factors Surgical treatment 


C cells

Thyroid follicular cells


Carcinoembryonic antigen




Fine-needle aspiration cytology


Medullary thyroid carcinoma


The odds ratio


RET proto-oncogene


Sporadic MTC




Funding Information

This study was supported by the National Key Clinical Specialty Discipline Construction Program of China (Grant Nos. 81472777, 30872479).

Compliance with Ethical Standards

This study was approved by the local Ethics Committee. All patients provided written informed consent before participating in the study.

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Dequanter D, et al. Medullary thyroid cancer: surgical results and prognostic factors. Rev Med Liege 2010, 65:450-452.Google Scholar
  2. 2.
    Dackiw AP, et al. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010, 43:365-374.CrossRefGoogle Scholar
  3. 3.
    Wells, SA, et al. Revised american thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015, 25(6):567-610.CrossRefGoogle Scholar
  4. 4.
    Leggett MD, et al. Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma. Ann Surg Oncol 2008, 15:2493-2499.CrossRefGoogle Scholar
  5. 5.
    Pinto AE, et al. Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behavior. Eur J Endocrinol 2014, 170:321-327.CrossRefGoogle Scholar
  6. 6.
    Alevizaki M, et al. Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression. Eur J Endocrinol 2012, 167:799-808.CrossRefGoogle Scholar
  7. 7.
    Milan SA, et al. Current management of medullary thyroid cancer. Minerva Chir 2010, 65:27-37.Google Scholar
  8. 8.
    Moley JF, et al. Patterns of nodal metastases in palpable Medullary thyroid carcinoma: recommendations for extent of nodedi section. AnnSurg 1999, 229:880-887.Google Scholar
  9. 9.
    Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014, 14:173-186.CrossRefGoogle Scholar
  10. 10.
    Kloos RT, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.CrossRefGoogle Scholar
  11. 11.
    Morrison PJ, et al. Genetic aspects of familial thyroid cancer. Oncologist 2009, 14:571-577.CrossRefGoogle Scholar
  12. 12.
    Kitamura Y, et al. Novel germ line RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 1997, 14:3103-3106.CrossRefGoogle Scholar
  13. 13.
    Koch CA, et al. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene 2001, 20:7809-7811.CrossRefGoogle Scholar
  14. 14.
    Roman S, et al. Prognosis of medullary thyroid carcinoma. Cancer 2006, 107:2134-2142.CrossRefGoogle Scholar
  15. 15.
    Machens A, et al. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surgery 2008, 95:586-591.CrossRefGoogle Scholar
  16. 16.
    Sanso GE, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002, 94:323-330.CrossRefGoogle Scholar
  17. 17.
    Lombardo F, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 2002, 87:1674-1680.CrossRefGoogle Scholar
  18. 18.
    Berndt I, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998, 83:770-774.Google Scholar
  19. 19.
    Raue F, et al. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009, 8:23-28.CrossRefGoogle Scholar
  20. 20.
    Heshmati HM, et al. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 1997, 72:430-436.CrossRefGoogle Scholar
  21. 21.
    Sarika HL, et al. Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades. Eur J Endocrinol 2015, 172:501-509.CrossRefGoogle Scholar
  22. 22.
    Machens A, et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millennium. Eur J Endocrinol 2013, 168:307-314.CrossRefGoogle Scholar
  23. 23.
    Machens A, et al. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities. J Intern Med 2009, 266:114-125.CrossRefGoogle Scholar
  24. 24.
    Menon M, et al. RET mutation status in medullary thyroid cancer (MTC) patients and the significance of genetic screening for mutations in their immediate relatives–a preliminary report. Indian J Pathol Microbiol 2005, 48:161-165.Google Scholar
  25. 25.
    Sharma BP, et al. RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients. J Biosci 2011, 36:603-611.CrossRefGoogle Scholar
  26. 26.
    Bao-Dong G, et al. Experimental study on the mutation rate of exon 16 codon 918 from RET proto-oncogene in different human races with sporadic medullary thyroid carcinoma. Chinese Journal of Experimental Surgery 2006, 23(3):319-321.Google Scholar
  27. 27.
    Saltiki K, et al. Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur J Endocrinol 2014, 171:117-126.CrossRefGoogle Scholar
  28. 28.
    Faggiano A, et al. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. J Clin Endocrinol Metab 2010, 95: E32-E36.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Thyroid SurgeryFujian Medical University Union HospitalFuzhouChina

Personalised recommendations